Spiriva

How to order Spiriva

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Spiriva on Prescriptsy

Spiriva is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Spiriva is one of the most widely prescribed maintenance inhalers for chronic obstructive pulmonary disease (COPD) in the United Kingdom.

It contains tiotropium bromide, a long-acting muscarinic antagonist (LAMA) that provides sustained bronchodilation for at least 24 hours with once-daily dosing.

Spiriva is available in two formulations: the Spiriva HandiHaler, which delivers 18 micrograms of tiotropium as a dry powder via a pierced capsule, and the Spiriva Respimat, which delivers 2.5 micrograms per puff (two puffs daily, total 5 micrograms) via a propellant-free soft mist inhaler.

COPD is a progressive respiratory condition affecting over 1.2 million diagnosed individuals in the UK, with an estimated further 2 million undiagnosed.

It is the second most common lung disease after asthma and a leading cause of death and disability, responsible for approximately 30,000 deaths and over 140,000 hospital admissions each year.

Effective long-term bronchodilator therapy is a cornerstone of COPD management, and tiotropium has the most extensive evidence base of any LAMA in this setting.

This page provides a comprehensive clinical overview of Spiriva, covering its mechanism of action, clinical evidence, device options, dosing, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Spiriva

Before reading further, note the following key safety points about Spiriva.

• Spiriva is a maintenance treatment. It must not be used as a reliever for sudden breathlessness. Always carry a short-acting bronchodilator (such as salbutamol) for acute symptoms.
• The Spiriva HandiHaler capsules must be inhaled using the HandiHaler device. They must not be swallowed.
• If you experience sudden eye pain, blurred vision, or visual halos, stop Spiriva immediately and seek urgent medical attention.
• Do not use Spiriva together with other anticholinergic bronchodilators such as ipratropium, glycopyrronium, or umeclidinium.

Understanding COPD

Chronic obstructive pulmonary disease is a common, progressive condition characterised by persistent airflow limitation that is usually associated with an enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases.

Cigarette smoking is the primary risk factor, but occupational exposures, indoor air pollution, and alpha-1 antitrypsin deficiency also contribute.

COPD encompasses two main pathological processes: chronic bronchitis, characterised by chronic productive cough due to mucus gland hyperplasia and goblet cell metaplasia, and emphysema, characterised by destruction of alveolar walls leading to loss of elastic recoil, air trapping, and impaired gas exchange.

The hallmark of COPD is persistent airflow limitation demonstrated by spirometry showing a post-bronchodilator FEV1/FVC ratio below 0.7.

Unlike asthma, the airflow limitation in COPD is not fully reversible, although bronchodilators provide meaningful symptomatic improvement by reducing air trapping, decreasing dynamic hyperinflation, and improving expiratory flow rates.

The severity of COPD is classified by NICE and GOLD using the post-bronchodilator FEV1 as a percentage of predicted: mild (at least 80%), moderate (50 to 79%), severe (30 to 49%), and very severe (below 30%).

How Spiriva works: mechanism of action

Tiotropium exerts its therapeutic effect by competitively blocking muscarinic acetylcholine receptors on airway smooth muscle cells and submucosal glands.

In the healthy lung, the parasympathetic nervous system maintains resting bronchomotor tone through release of acetylcholine, which acts on muscarinic M3 receptors to cause smooth muscle contraction and stimulate mucus secretion.

In COPD, vagal cholinergic tone is increased and represents the major reversible component of airflow obstruction.

Tiotropium binds to all five muscarinic receptor subtypes (M1 to M5) but has kinetic selectivity for M3 and M1 receptors, dissociating from M3 receptors with a half-life of approximately 35 hours compared with 3.6 hours for M2 receptors.

This prolonged M3 receptor occupancy underpins the sustained 24-hour bronchodilator effect and permits once-daily dosing.

The slow dissociation from M1 receptors in parasympathetic ganglia may also contribute to reduced vagal-mediated bronchoconstriction.

By blocking M3 receptors, tiotropium reduces bronchoconstriction, decreases mucus secretion, reduces air trapping, and improves exercise tolerance. These effects translate into reduced breathlessness, improved lung function, fewer exacerbations, and enhanced quality of life in patients with COPD.

Clinical evidence for Spiriva

Tiotropium is the most extensively studied LAMA for COPD. Key clinical trials include UPLIFT, TIOSPIR, and POET-COPD.

The UPLIFT trial

The Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial was a landmark 4-year, randomised, double-blind, placebo-controlled study involving 5,993 patients with moderate to very severe COPD.

Tiotropium 18 micrograms once daily (HandiHaler) demonstrated sustained improvements in pre-bronchodilator FEV1 (87 to 103 mL above placebo at all time points), reduced exacerbation rates by 14%, and improved quality of life as measured by the SGRQ.

Although tiotropium did not significantly alter the rate of decline in FEV1 (the primary endpoint), it reduced the risk of respiratory failure and cardiac events in post-hoc analyses.

The TIOSPIR trial

The Tiotropium Safety and Performance in Respimat (TIOSPIR) trial was designed to compare the safety of Spiriva Respimat with Spiriva HandiHaler following earlier concerns about cardiovascular safety with the Respimat formulation.

This large-scale trial (17,135 patients, median follow-up 2.3 years) found no difference in the risk of death or major cardiovascular events between Respimat and HandiHaler, confirming the cardiovascular safety of both formulations.

The efficacy of the two formulations was also similar, validating clinical equivalence despite the different delivered doses (5 micrograms Respimat versus 18 micrograms HandiHaler).

POET-COPD

The Prevention of Exacerbations with Tiotropium in COPD (POET-COPD) trial compared tiotropium 18 micrograms once daily with salmeterol 50 micrograms twice daily in 7,376 patients with moderate to very severe COPD and a history of exacerbations.

Tiotropium reduced the risk of exacerbations by 17% compared with salmeterol, establishing LAMA therapy as superior to LABA monotherapy for exacerbation prevention.

This finding has influenced national and international COPD guidelines, including NICE NG115.

Where Spiriva fits in UK COPD management

NICE guideline NG115 recommends that patients with confirmed COPD who remain symptomatic despite short-acting bronchodilators should be started on a long-acting bronchodilator as maintenance therapy.

A LAMA (such as tiotropium) is generally preferred as the first-line long-acting bronchodilator due to its superior exacerbation prevention compared with LABA monotherapy (as demonstrated in the POET-COPD trial).

If a single bronchodilator does not adequately control symptoms, the next step is to add a second bronchodilator from the other class (LAMA plus LABA), which can be achieved with a combination inhaler such as Spiolto Respimat.

For patients with asthmatic features, raised blood eosinophils (at or above 300 cells per microlitre), or frequent exacerbations despite LAMA/LABA therapy, NICE recommends considering the addition of an inhaled corticosteroid (triple therapy).

In patients without these features, the LAMA (or LAMA/LABA) pathway without ICS is preferred to avoid the pneumonia risk associated with long-term ICS use in COPD.

Choosing between HandiHaler and Respimat

Both formulations of Spiriva deliver clinically equivalent bronchodilation, and the choice between them is guided by patient preference, inspiratory ability, and practical considerations.

The HandiHaler is a dry powder inhaler (DPI) that requires a moderate to strong inspiratory effort (peak inspiratory flow rate of at least 20 litres per minute) to de-aggregate the powder and achieve adequate lung deposition.

It is simple to use, has no priming requirement (each capsule is individually loaded), and provides audible feedback (capsule rattling) that the dose is being inhaled correctly.

However, patients with severe airflow limitation or those who are acutely unwell may not generate sufficient inspiratory flow.

The Respimat is a soft mist inhaler that generates a slow-moving aerosol lasting approximately 1.5 seconds, requiring minimal inspiratory effort.

It achieves higher lung deposition (approximately 50 to 60%) than the HandiHaler (approximately 20 to 30%) at a lower nominal dose, which accounts for the difference in labelled doses (5 micrograms versus 18 micrograms).

The Respimat requires priming and a slightly more complex loading procedure, but is often preferred for patients with poor inspiratory flow or those who find the coordination of a pMDI difficult.

Side effects of Spiriva

Common side effects

Dry mouth is the most frequently reported side effect, occurring in approximately 4 to 16% of patients. It is generally mild and may improve with continued use.

Practical measures include regular sipping of water, using sugar-free chewing gum or lozenges, and maintaining good oral hygiene.

Persistent dry mouth may increase the risk of dental caries, so regular dental check-ups are advisable.

Less common side effects

Dizziness, headache, cough on inhalation, pharyngitis, hoarseness, oral thrush, constipation, and urinary difficulties (particularly in men with prostatic hyperplasia) have been reported. Urinary retention is uncommon but may require medical intervention if it occurs.

Rare and serious side effects

Acute angle-closure glaucoma is a rare but serious adverse effect that can cause permanent visual damage if not treated promptly.

Symptoms include sudden eye pain, red eye, blurred vision, and seeing halos around lights. Patients should stop Spiriva and seek immediate ophthalmic assessment.

Other rare effects include atrial fibrillation, supraventricular tachycardia, paradoxical bronchospasm, angioedema, anaphylaxis, and intestinal obstruction. Severe skin reactions (Stevens-Johnson syndrome) are very rare.

When to seek medical advice

Contact your GP, pharmacist, or NHS 111 if you develop persistent or troublesome dry mouth, difficulty passing urine, new constipation, or other symptoms you think may be related to Spiriva.

Seek emergency care by calling 999 or attending A&E if you have sudden eye pain or visual disturbance, severe difficulty breathing not relieved by your reliever inhaler, chest pain, rapid or irregular heartbeat, or signs of a severe allergic reaction including facial or throat swelling.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Not for acute relief

Spiriva is a maintenance treatment and must not be used for the relief of acute breathlessness or bronchospasm.

Increasing breathlessness despite regular use may indicate an exacerbation requiring prompt medical review, possible oral corticosteroids, and antibiotics if bacterial infection is suspected.

Glaucoma and urinary retention

Patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction should use Spiriva with caution. The anticholinergic effect of tiotropium can worsen these conditions. Patients should be counselled about warning signs and advised to seek immediate medical attention if needed.

Renal impairment

Tiotropium is partially excreted by the kidneys. Plasma levels increase with declining renal function.

In patients with moderate to severe renal impairment, Spiriva should be used only if the anticipated benefit outweighs the potential risk, and patients should be monitored for anticholinergic side effects.

Lactose content (HandiHaler only)

The HandiHaler capsules contain lactose monohydrate, which includes trace amounts of milk protein. Patients with known severe milk protein allergy should not use the HandiHaler; Spiriva Respimat, which is lactose-free, is a suitable alternative.

How to get a Spiriva prescription in the UK

Spiriva is classified as a prescription-only medicine (POM). It is commonly prescribed by GPs, respiratory nurses, and hospital respiratory physicians following a confirmed COPD diagnosis based on spirometry.

Repeat prescriptions may be issued through GP surgeries or authorised online prescribers registered with the GPhC. Spiriva is available on the NHS.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Smoking cessation and COPD management

Stopping smoking is the single most effective intervention for slowing the progression of COPD and is recommended at every stage of the disease.

The NHS provides free stop smoking services including behavioural support, nicotine replacement therapy, and prescription medicines such as varenicline.

Combining smoking cessation with effective maintenance bronchodilator therapy such as Spiriva gives the best chance of preserving lung function and reducing future exacerbations and hospitalisations.

Other key components of COPD management include pulmonary rehabilitation, annual influenza and one-off pneumococcal vaccinations, nutritional support, and self-management action plans agreed with the clinical team.

Sources

• Spiriva HandiHaler 18 micrograms, Summary of Product Characteristics (EMC)
• Spiriva Respimat 2.5 micrograms, Summary of Product Characteristics (EMC)
• Tiotropium, British National Formulary (BNF)
• NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
• GOLD: Global Initiative for Chronic Obstructive Lung Disease
• COPD, NHS
• MHRA Yellow Card Scheme